Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.
Thrilled to be part of the GRObio mission! Congratulations to the team! https://t.co/Xe6gSujYHV
Dan and his team are pushing ahead with their revolutionary vision. Non-standard amino acids allowing for novel proteins, useful across multiple diseases and situations. Pillar has been glad to back GRObio from the pre-Seed til now, with a wonderful and expanding syndicate. https://t.co/pqF5LhRBF9
I am thrilled to announce @gro_bio's $60.3M Series B financing, co-led by @atlasventure and Access Biotechnology! This financing is the culmination of an enormous body of work by our entire company, including our GRO platform, product pipeline, and business development personnel,…